Linden Advisors’s Ibere Pharmaceuticals IBER Stock Holding History

Linden Advisors’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-450,000	Closed	-$4.54M	–	566
2022 Q4	$4.54M	Hold	450,000	–	–	0.05%	217
2022 Q3	$4.46M	Hold	450,000	–	–	0.04%	241
2022 Q2	$4.41M	Hold	450,000	–	–	0.04%	262
2022 Q1	$4.41M	Hold	450,000	–	–	0.03%	353
2021 Q4	$4.37M	Hold	450,000	–	–	0.03%	332
2021 Q3	$4.36M	Hold	450,000	–	–	0.03%	332
2021 Q2	$4.35M	Buy	+450,000	New	+$4.38M	0.02%	361

Linden Advisors's IBER Position: Q1 2023 in Review

Linden Advisors sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 450,000 shares — an estimated $4.54M sold.

Linden Advisors first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $4.54M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Linden Advisors reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Linden Advisors sold 450,000 Ibere Pharmaceuticals shares in Q1 2023, an estimated $4.54M.
Linden Advisors first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Linden Advisors's Ibere Pharmaceuticals position peaked at $4.54M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Linden Advisors's 13F filing for Q1 2023, filed 15 May 2023.